Beta Bionics, Inc. (BBNX)
NASDAQ: BBNX · Real-Time Price · USD
22.45
+0.30 (1.35%)
Oct 8, 2025, 2:21 PM EDT - Market open

Beta Bionics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22
78.0265.12120.18
Revenue Growth (YoY)
550.45%442.93%6601.12%-
Cost of Revenue
35.9529.245.69-
Gross Profit
42.0835.896.310.18
Selling, General & Admin
73.7954.9624.2233.5
Research & Development
30.8226.1817.9431.43
Operating Expenses
104.6181.1442.1664.92
Operating Income
-62.53-45.25-35.85-64.74
Interest Expense
----0.01
Interest & Investment Income
7.223.911.780.2
Other Non Operating Income (Expenses)
-18.06-13.41-10.030.91
EBT Excluding Unusual Items
-73.37-54.76-44.1-63.65
Other Unusual Items
----1.1
Pretax Income
-73.37-54.76-44.1-64.75
Net Income
-73.37-54.76-44.1-64.75
Net Income to Common
-73.37-54.76-44.1-64.75
Shares Outstanding (Basic)
22655
Shares Outstanding (Diluted)
22655
Shares Change (YoY)
312.49%20.01%6.13%-
EPS (Basic)
-3.35-8.60-8.31-12.96
EPS (Diluted)
-3.35-8.60-8.31-12.96
Free Cash Flow
-62.06-51.67-32.85-60.98
Free Cash Flow Per Share
-2.84-8.12-6.19-12.20
Gross Margin
53.93%55.11%52.59%100.00%
Operating Margin
-80.14%-69.48%-298.88%-36169.83%
Profit Margin
-94.04%-84.08%-367.64%-36173.74%
Free Cash Flow Margin
-79.53%-79.34%-273.84%-34067.04%
EBITDA
-61.31-44.1-34.62-63.4
EBITDA Margin
-78.58%-67.72%-288.65%-
D&A For EBITDA
1.221.151.231.35
EBIT
-62.53-45.25-35.85-64.74
EBIT Margin
-80.14%-69.48%-298.87%-
Revenue as Reported
---0.18
Updated Jul 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q